On Thursday, Piper Sandler reaffirmed its Overweight rating on shares of Ocular Therapeutix (NASDAQ:OCUL), with a steady price target of $15.00. The firm's stance comes after insights were gained from a competitor's research and development presentation. Eyepoint Pharmaceuticals, a competitor to Ocular Therapeutix, recently shared details about its Phase 3 wet Age-related Macular Degeneration (AMD (NASDAQ:AMD)) programs for Duravyu, which is seen as a direct competitor to Ocular Therapeutix's Axpaxli.
Eyepoint Pharmaceuticals unveiled topline 12-month data from the Phase 2 DAVIO 2 study in wet AMD. According to Piper Sandler, the Phase 3 study design presented by Eyepoint is considered "relatively vanilla," with a notable distinction being the absence of a SOL-1 like superiority trial design, which is part of Ocular Therapeutix's program.
The management at Eyepoint emphasized that their study would include both treatment-experienced and treatment-naive patients. Additionally, the study is designed with a non-inferiority objective. Piper Sandler noted that at a first glance, Eyepoint's approach could introduce a greater variability, which may have subsequent implications on the statistical planning for the study.
Ocular Therapeutix's Axpaxli is among the treatments in the company's pipeline that are being developed to address the needs of patients with eye diseases.
In other recent news, Ocular Therapeutix has witnessed several significant developments. The biopharmaceutical company's stock was upgraded from a Hold to a Buy rating by TD Cowen, with the price target being increased to $11. This positive reassessment was based on advancements in the company's clinical programs, particularly the SOL-1 trial. H.C. Wainwright also reiterated its Buy rating for the company, adjusting its price target to $14.
Ocular Therapeutix has made steady progress in its pivotal SOL-1 trial for AXPAXLI, a treatment for wet Age-related Macular Degeneration (AMD). The trial's successful progress was attributed to the experienced team and strong support from key opinion leaders. The company also announced a workforce reduction primarily affecting its research and development and technical operations departments, aiming to concentrate resources on the clinical development of AXPAXLI.
In terms of financial performance, Ocular Therapeutix reported Q1 2024 revenues of $14.8 million, a 10.5% year-over-year increase, and a net loss of $64.8 million due to one-time expenses. The company also appointed Dr. Pravin U. Dugel as its President and Chief Executive Officer.
InvestingPro Insights
In light of Piper Sandler's reaffirmed Overweight rating on Ocular Therapeutix, it is valuable to consider the company's financial health and market performance. InvestingPro data shows that Ocular Therapeutix holds a market capitalization of approximately $1.03 billion. Despite challenges highlighted by a negative P/E ratio of -5.35 and a more adjusted P/E ratio for the last twelve months as of Q1 2024 at -9.93, the company has demonstrated a revenue growth of 15.79% in the same period. This suggests that while profitability is a current issue, as also indicated by a negative gross profit margin of -21.04%, there is growth potential in the company's operations.
InvestingPro Tips for Ocular Therapeutix reveal a mixed picture. On the positive side, the company holds more cash than debt and has liquid assets that exceed short-term obligations, providing some financial stability. However, analysts have revised earnings downwards for the upcoming period, and the company is not expected to be profitable this year. Despite these concerns, significant returns over the last week and month, with a 9.05% and 14.41% total price return respectively, may catch the interest of investors looking for short-term gains.
For those interested in a more in-depth analysis, InvestingPro offers additional insights, including a total of 11 InvestingPro Tips for Ocular Therapeutix, which can be found at https://www.investing.com/pro/OCUL. To explore these insights further, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.